Entacapone and Prostate Cancer Risk in Patients With Parkinson's Disease

E-ISSN： 1531-8257|30|5|724-728

ISSN： 0885-3185

Source： MOVEMENT DISORDERS, Vol.30, Iss.5, 2015-04, pp. : 724-728

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Avoiding surgery in prostate cancer patients with low-risk disease

By Mouraviev Vladimir Polascik Thomas J

Therapy, Vol. 5, Iss. 1, 2008-01 ,pp. : 25-36

Future Medicine

Access to resources Recommend Favorite

Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off

By Findley Leslie J Lees Andrew Apajasalo Marjo Pitkänen Anna Turunen Heidi

Current Medical Research and Opinion, Vol. 21, Iss. 7, 2005-07 ,pp. : 1005-1014

Informa Healthcare

Access to resources Recommend Favorite

Identification of pathologically favorable disease in intermediate‐risk prostate cancer patients: Implications for active surveillance candidates selection

THE PROSTATE, Vol. 75, Iss. 13, 2015-09 ,pp. : 1484-1491

John Wiley & Sons Inc

Access to resources Recommend Favorite

Stratification of patients with intermediate‐risk prostate cancer

BJU INTERNATIONAL, Vol. 115, Iss. 6, 2015-06 ,pp. : 907-912

John Wiley & Sons Inc

Access to resources Recommend Favorite

Importance of prostate volume in the stratification of patients with intermediate‐risk prostate cancer

INTERNATIONAL JOURNAL OF UROLOGY, Vol. 22, Iss. 6, 2015-06 ,pp. : 555-561

John Wiley & Sons Inc

Access to resources Recommend Favorite